Merck Sharp Dohme Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MERCK SHARP DOHME, and what generic alternatives to MERCK SHARP DOHME drugs are available?
MERCK SHARP DOHME has twenty-three approved drugs.
There are twenty-five US patents protecting MERCK SHARP DOHME drugs.
There are six hundred and ninety patent family members on MERCK SHARP DOHME drugs in sixty-three countries and one hundred and twenty-seven supplementary protection certificates in nineteen countries.
Summary for Merck Sharp Dohme
International Patents: | 690 |
US Patents: | 25 |
Tradenames: | 19 |
Ingredients: | 19 |
NDAs: | 23 |
Drugs and US Patents for Merck Sharp Dohme
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merck Sharp Dohme | VERQUVO | vericiguat | TABLET;ORAL | 214377-001 | Jan 19, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Merck Sharp Dohme | NOXAFIL | posaconazole | SOLUTION;INTRAVENOUS | 205596-001 | Mar 13, 2014 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Merck Sharp Dohme | PREVYMIS | letermovir | TABLET;ORAL | 209939-002 | Nov 8, 2017 | RX | Yes | Yes | RE46791 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Merck Sharp Dohme | NOXAFIL | posaconazole | SOLUTION;INTRAVENOUS | 205596-001 | Mar 13, 2014 | AP | RX | Yes | Yes | 10,117,951 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Merck Sharp Dohme | VERQUVO | vericiguat | TABLET;ORAL | 214377-001 | Jan 19, 2021 | RX | Yes | No | 8,420,656 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Merck Sharp Dohme | PREVYMIS | letermovir | TABLET;ORAL | 209939-001 | Nov 8, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Merck Sharp Dohme
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Merck Sharp Dohme | JANUVIA | sitagliptin phosphate | TABLET;ORAL | 021995-001 | Oct 16, 2006 | 7,459,428 | ⤷ Try a Trial |
Merck Sharp Dohme | REBETOL | ribavirin | CAPSULE;ORAL | 020903-001 | Jun 3, 1998 | 5,914,128*PED | ⤷ Try a Trial |
Merck Sharp Dohme | JUVISYNC | simvastatin; sitagliptin phosphate | TABLET;ORAL | 202343-004 | Sep 18, 2012 | 7,459,428 | ⤷ Try a Trial |
Merck Sharp Dohme | REBETOL | ribavirin | CAPSULE;ORAL | 020903-001 | Jun 3, 1998 | 6,461,605*PED | ⤷ Try a Trial |
Merck Sharp Dohme | JANUVIA | sitagliptin phosphate | TABLET;ORAL | 021995-001 | Oct 16, 2006 | 6,303,661 | ⤷ Try a Trial |
Merck Sharp Dohme | JUVISYNC | simvastatin; sitagliptin phosphate | TABLET;ORAL | 202343-001 | Oct 7, 2011 | 8,168,637 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MERCK SHARP DOHME drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 140 mg and 180 mg | ➤ Subscribe | 2008-03-24 |
➤ Subscribe | Delayed-release Tablets | 100 mg | ➤ Subscribe | 2014-06-16 |
➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2006-06-21 |
➤ Subscribe | Tablets | 25 mg, 50 mg and 100 mg | ➤ Subscribe | 2010-10-18 |
➤ Subscribe | Tablets | 100 mg/10 mg and 100 mg/40 mg | ➤ Subscribe | 2012-06-25 |
➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2011-02-28 |
➤ Subscribe | Injection | 18 mg/mL, 16.7 mL vials | ➤ Subscribe | 2015-11-24 |
➤ Subscribe | Orally Disintegrating Tablets | 2.5 mg and 5 mg | ➤ Subscribe | 2006-06-21 |
➤ Subscribe | Tablets | 100 mg/10 mg and 100 mg/40 mg | ➤ Subscribe | 2012-06-19 |
➤ Subscribe | Tablets | 50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg | ➤ Subscribe | 2012-11-06 |
International Patents for Merck Sharp Dohme Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Hungary | E052080 | ⤷ Try a Trial |
South Korea | 100904788 | ⤷ Try a Trial |
Mexico | 369666 | ⤷ Try a Trial |
South Korea | 102026059 | ⤷ Try a Trial |
European Patent Office | 1654263 | ⤷ Try a Trial |
Taiwan | 201838993 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Merck Sharp Dohme Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1385870 | 300506 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: BOCEPREVIR, OF EEN ENANTIOMEER, STEREOISIOMEER, ROTAMEER, TAUTOMEER OF RACEMAAT VAN DIE VERBINDING, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT; REGISTRATION NO/DATE: EU/1/11/704/001 20110718 |
1441735 | 319 | Finland | ⤷ Try a Trial | |
1622880 | 2018C/025 | Belgium | ⤷ Try a Trial | PRODUCT NAME: LETERMOVIR, DESGEWENST IN DE VORM VAN EEN ZOUT OF SOLVAAT ERVAN OF EEN SOLVAAT VAN EEN ZOUT; AUTHORISATION NUMBER AND DATE: EU/1 /1 7/1245 20170110 |
1441735 | C01441735/01 | Switzerland | ⤷ Try a Trial | FORMER OWNER: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A., IT |
1622880 | C 2018 027 | Romania | ⤷ Try a Trial | PRODUCT NAME: LETERMOVIR SAU SAREA SA, SOLVATUL SAU, SAU SOLVATUL SARII SALE; NATIONAL AUTHORISATIONNUMBER: EU/1/17/1245; DATE OF NATIONAL AUTHORISATION: 20180108; NUMBER OF FIRST AUTHORISATION IN EU ROPEAN ECONOMIC AREA (EEA): EU/1/17/1245; DATE OF FIRST AUTHORISATION IN EEA: 20180108 |
1622880 | LUC00070 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: LETERMOVIR; AUTHORISATION NUMBER AND DATE: EU71/17/1245 20180110 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.